3
Clinical Trials associated with BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
A Single-Arm, Single-Center Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma
This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for multiple myeloma.
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With R/R MM Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
100 Clinical Results associated with BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)
100 Translational Medicine associated with BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)
100 Patents (Medical) associated with BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)
100 Deals associated with BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)